Monitor for prospectus supplements that would indicate actual capital raise size and terms. The shelf gives management flexibility but the I.B.6 limit restricts primary sales to ~$11.5M in any 12-month period given the current $34.6M public float, unless the float increases or the company qualifies for full shelf access.
ACRV drugs
ACRV drug pipeline →Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Acrivon Therapeutics filed a new S-3 shelf registration statement for up to $300 million in securities (common stock, preferred stock, debt securities, warrants, units), replacing a prior shelf with $292.7 million of unsold securities carried forward. The filing comes on the same day as Q3 2026 results showing $77.8 million in cash, expected to fund operations into Q4 2027, and no immediate pricing or offering was announced. The shelf provides broad financing flexibility for a clinical-stage biotech with no revenue and ongoing losses.
Key Financial Metrics
Key Facts
- S-3 shelf registration filed for up to $300,000,000 in aggregate securities
- $292,701,082.80 of unsold securities carried forward from prior S-3 (File No. 333-275854)
- $7,298,917.20 of newly registered securities; registration fee of $635.01
- Filed on same day as Q3 2026 earnings release and 10-Q
- Cash, cash equivalents, and marketable securities of $77.8 million as of September 30, 2026
- Company expects cash to fund operations into Q4 2027
- Public float approximately $34.6 million; subject to I.B.6 one-third public float limit on primary sales
- No specific offering, pricing, or terms announced in the filing
Financial Impact
Shelf registration of up to $300 million; no immediate capital raise. Company had $77.8M cash as of Sept 30, 2026.
Risk Factors
- Potential future dilution from any equity or convertible issuance under the shelf
- Company is pre-revenue with recurring losses; may need to access this shelf for funding
- I.B.6 restriction limits primary sales to ~one-third of public float ($34.6M) in any 12-month period
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-463828 |
| Document: d185923dex43.htm | 0001193125-26-463828 |
| Document: d185923dexfilingfees.htm | 0001193125-26-463828 |
| Document: d185923dex51.htm | 0001193125-26-463828 |
| Document: d185923dex231.htm | 0001193125-26-463828 |
| Document: 0001193125-26-463828-index-headers.html | 0001193125-26-463828 |
Track record
9 reports on ACRV
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 20261d ago S-3 Neutral 3/10 Viewing Entry $1.45 Now $1.43 −1.38% settles Feb 16
- Nov 16, 20261d ago Press Release Neutral 4/10 Entry $1.45 Now $1.43 −1.38% settles Feb 16
- Nov 10, 20267d ago 8-K Neutral 4/10 Entry $1.57 Now $1.43 −8.92% settles Feb 9
- Nov 6, 202611d ago 8-K Neutral 5/10 Entry $1.61 Now $1.43 −11.18% settles Feb 4
- Nov 6, 202611d ago Press Release Neutral 4/10 Entry $1.61 Now $1.43 −11.18% settles Feb 4
- Jul 21, 202617w ago Press Release Neutral 3/10 Entry $1.68 to $1.76 Now $1.43 −14.88% ▲ +4.76% +1.50% vs SPY
- May 22, 202625w ago DEFA14A Neutral 3/10 Entry $1.67 to $2.39 Now $1.43 −14.37% ▲ +43.11% +40.39% vs SPY
- Apr 30, 202628w ago DEFA14A Neutral 2/10 Entry $1.85 to $1.56 Now $1.43 −22.70% ▼ −15.68% −18.78% vs SPY
- Mar 19, 202634w ago Press Release Bullish 8/10 Entry $1.70 to $1.52 Now $1.43 −15.88% ▼ −10.59% −24.93% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers